With facilities in Brandford CT and in Cleveland OH where the firm has ties to Case Western University, Aeromics is developing new small molecule therapeutics, exploiting a novel target for the treatment of CNS edema. The company is building out from the foundersâ expertise in the biological control of water and gas permeation in pathological and normal tissues. Water is essential to life, but it can also be life threatening. Aeromics is using a new understanding of water physiology to advance the development of novel therapeutics. Patients suffering from a long list of conditions including stroke, traumatic brain injury, and congestive heart failure all have important complications resulting from the disturbed compartmentalization of water. The firm's drugs reduce the movement of water between compartments with the potential impact of significantly improving patient outcomeAeromics, Inc. is a clinical-stage pharmaceutical company developing an intravenously administered aquaporin-4 (AQP4) inhibitor (AER-271) for severe, acute ischemic stroke that will prevent or arrest brain swelling (cerebral edema) following an ischemic event. By preventing brain swelling AER-271 will significantly improve survival following an ischemic brain event, lead to better outcomes and more complete and faster recovery and reduce the need for more invasive treatments such as decompressive craniectomy. Aeromics is currently investigating the pharmacokinetics, safety and tolerability of AER-271 in a Phase 1 clinical trial
